Latest stories on CANF
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
TipRanks63 · neutralproduct/pr
Biggest stock movers Thursday: FIZZ, CANF, and more
Seeking Alpha50 · neutralgeneral
CANF Announces Phase 2a Results: Namodenoson Shows Durable Survival in Advanced Pancreatic Cancer
MarketChameleon67 · bullishproduct/pr
Why Is CANF Stock Surging Today?
Stocktwits News63 · neutralproduct/pr
Can-Fite’s Namodenoson Shows Durable Survival in Advanced Pancreatic Cancer Phase 2a Study—Primary Safety Endpoint Achieved
MarketChameleon67 · bullishproduct/pr
CANF Stock Pulls Back After Patent-Fueled Surge – Retail Calls It Consolidation Ahead Of Next Leg Up
Stocktwits News56 · neutralproduct/pr
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology | CANF Stock News
StockTitan63 · neutralproduct/pr
Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
TipRanks63 · neutralproduct/pr
Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026
TipRanks56 · neutralproduct/pr
Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer
TipRanks67 · bullishproduct/pr
Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum
TipRanks34 · bearishgeneral